US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by GSK plc

News headline image
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
Tickers GSK
News headline image
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
From GSK plc
Via Business Wire
Tickers GSK
News headline image
US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
From GSK plc
Via Business Wire
Tickers GSK
News headline image
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
From GSK plc
Via Business Wire
Tickers GSK
News headline image
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older
From GSK plc
Via Business Wire
Tickers GSK
News headline image
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
From GSK plc
Via Business Wire
Tickers GSK
News headline image
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
From GSK plc
Via Business Wire
Tickers GSK
News headline image
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
From GSK plc
Via Business Wire
Tickers GSK
News headline image
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
From GSK plc
Via Business Wire
Tickers GSK
News headline image
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
From GSK plc
Via Business Wire
Tickers GSK
News headline image
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
Tickers GSK